New cell sources for CAR-based immunotherapy

Mazinani, Marzieh; Rahbarizadeh, Fatemeh

doi:10.1186/s40364-023-00482-9

Cited by 25 publications

(4 citation statements)

References 246 publications

(319 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For solid tumor, due to its several characteristics, including their heterogeneity, toxicities, hostile tumor microenvironment (TME), and limited infiltration of immune cells ( 6 ), CAR-T cell therapy has been far less impressive in solid tumor. Although there are numerous popular targets, such as CD19, BCMA, CD20, HER-2, MSLN, and GD2, etc ( 7 , 8 ). But, this requires redesigning each CAR molecule for each target, which leads to high initial research costs and slow progress in clinical application.…”

Section: Introductionmentioning

confidence: 99%

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Tang,

Sun,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundChimeric antigen receptor T (CAR-T) cell therapies have achieved remarkable success in the treatment of hematological tumors. However, given the distinct features of solid tumors, particularly heterogeneity, metabolic aggressiveness, and fewer immune cells in tumor microenvironment (TME), the practical utility of CAR-T cells for solid tumors remains as a challenging issue. Meanwhile, although anti-PD-1 monoclonal antibody (mAb) has shown clinical efficacy, most mAbs also show limited clinical benefits for solid tumors due mainly to the issues associated with the lack of immune cells in TME. Thus, the infiltration of targeted immunological active cells into TME could generate synergistic efficacy for mAbs.MethodsWe present a combinational strategy for solid tumor treatment, which combines armored-T cells to express Fc-gamma receptor I (FcγRI) fragment on the surfaces for targeting various tumors with therapeutically useful mAbs. Choosing CD20 and HER-2 as the targets, we characterized the in vitro and in vivo efficacy and latent mechanism of the combination drug by using flow cytometry, ELISA and other methods.ResultsThe combination and preprocessing of armored T-cells with corresponding antibody of Rituximab and Pertuzumab exerted profound anti-tumor effects, which is demonstrated to be mediated by synergistically produced antibody-dependent cellular cytotoxicity (ADCC) effects. Meanwhile, mAb was able to carry armored-T cell by preprocessing for the infiltration to TME in cell derived xenograft (CDX) model.ConclusionsThis combination strategy showed a significant increase of safety profiles from the reduction of antibody doses. More importantly, the present strategy could be a versatile tool for a broad spectrum of cancer treatment, with a simple pairing of engineered T cells and a conventional antibody.

show abstract

Section: Introductionmentioning

confidence: 99%

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Tang,

Sun,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Adenovirus is another vehicle for macrophages that have been utilized as viral vectors. The high expression of CD46 in macrophage surfaces mediates the docking protein for group B adenoviruses, such as Ad35 [ 116 , 117 ]. Next, a replication-incompetent chimeric adenoviral vector Ad5f35 was evaluated as gene-delivery to macrophages that expressed CAR with high efficiency [ 105 ].…”

Section: Introductionmentioning

confidence: 99%

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors

Hadiloo,

Taremi,

Heidari

et al. 2023

Biomark Res

View full text Add to dashboard Cite

Today, adoptive cell therapy has many successes in cancer therapy, and this subject is brilliant in using chimeric antigen receptor T cells. The CAR T cell therapy, with its FDA-approved drugs, could treat several types of hematological malignancies and thus be very attractive for treating solid cancer. Unfortunately, the CAR T cell cannot be very functional in solid cancers due to its unique features. This treatment method has several harmful adverse effects that limit their applications, so novel treatments must use new cells like NK cells, NKT cells, and macrophage cells. Among these cells, the CAR macrophage cells, due to their brilliant innate features, are more attractive for solid tumor therapy and seem to be a better candidate for the prior treatment methods. The CAR macrophage cells have vital roles in the tumor microenvironment and, with their direct effect, can eliminate tumor cells efficiently. In addition, the CAR macrophage cells, due to being a part of the innate immune system, attended the tumor sites. With the high infiltration, their therapy modulations are more effective. This review investigates the last achievements in CAR-macrophage cells and the future of this immunotherapy treatment method.

show abstract

“…For solid tumor, due to its several characteristics, including their heterogeneity, toxicities, hostile tumor microenvironment (TME), and limited infiltration of immune cells (6), CAR-T cell therapy has been far less impressive in solid tumor. Although there are numerous popular targets, such as CD19, BCMA, CD20, HER-2, MSLN, and GD2, etc (7,8). But, this requires redesigning each CAR molecule for each target, which leads to high initial research costs and slow progress in clinical application.…”

Section: Introductionmentioning

confidence: 99%

Image_4.tif

View full text Add to dashboard Cite

New cell sources for CAR-based immunotherapy

Cited by 25 publications

References 246 publications

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

Broadening anticancer spectrum by preprocessing and treatment of T- lymphocytes expressed FcγRI and monoclonal antibodies for refractory cancers

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors

Image_4.tif

Contact Info

Product

Resources

About